FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GIVEN BRUCE D
2. Issuer Name and Ticker or Trading Symbol

ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Operating Officer
(Last)          (First)          (Middle)

177 E. COLORADO BLVD, SUITE 700
3. Date of Earliest Transaction (MM/DD/YYYY)

4/20/2020
(Street)

PASADENA, CA 91105
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 4/20/2020  M  3800 A$4.75 862793 D  
Common Stock 4/20/2020  M  3700 A$5.19 866493 D  
Common Stock 4/20/2020  M  3456 A$5.20 869949 D  
Common Stock 4/20/2020  M  5300 A$14.54 875249 D  
Common Stock 4/20/2020  S(1)  3800 D$40.00 (2)871449 D  
Common Stock 4/20/2020  S(1)  3700 D$40.00 (3)867749 D  
Common Stock 4/20/2020  S(1)  3456 D$40.00 (2)864293 D  
Common Stock 4/20/2020  S(1)  5300 D$40.00 (3)858993 D  
Common Stock 4/20/2020  S(1)  3454 D$40.00 (2)855539 D  
Common Stock 4/20/2020  S(1)  3805 D$40.00 (2)851734 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $4.75 4/20/2020  M     3800  10/1/2013 (4)9/21/2023 Common Stock 3800 $0.00 346200 D  
Stock Option (right to buy) $5.19 4/20/2020  M     3700  3/1/2012 (4)2/16/2022 Common Stock 3700 $0.00 342500 D  
Stock Option (right to buy) $5.20 4/20/2020  M     3456  4/1/2012 (4)10/26/2021 Common Stock 3456 $0.00 339044 D  
Stock Option (right to buy) $14.54 4/20/2020  M     5300  3/1/2014 (4)2/6/2024 Common Stock 5300 $0.00 333744 D  

Explanation of Responses:
(1) Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
(2) The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
(3) The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4
(4) Represents first vesting date. Option vested over four years from date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
GIVEN BRUCE D
177 E. COLORADO BLVD
SUITE 700
PASADENA, CA 91105


Chief Operating Officer

Signatures
/S/ Bruce Given4/22/2020
**Signature of Reporting PersonDate

Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Arrowhead Pharmaceuticals Charts.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Arrowhead Pharmaceuticals Charts.